Prostate cancer (PC) is the most common non-cutaneous cancer in men worldwide. The relationships between PC and possible risk factors for PC cases (n 5 1,181) and male controls (n 5 875) from the New South Wales (NSW) Cancer, Lifestyle and Evaluation of Risk Study (CLEAR) were examined in this study. The associations between PC risk and paternal history of PC, body mass index (BMI), medical conditions, sexual behaviour, balding pattern and puberty, after adjusting for age, income, region of birth, place of residence, and PSA testing, were examined. Adjusted risk of PC was higher for men with a paternal history of PC (OR 5 2.31; 95%CI: 1.70-3.14), personal history of prostatitis (OR 5 2.30; 95%CI: 1.44-3.70), benign prostatic hyperplasia (OR 5 2.29; 95%CI: 1.79-2.93), being overweight (vs. normal; OR 5 1.24; 95%CI: 0.99-1.55) or obese (vs. normal; OR 5 1.44; 95%CI: 1.09-1.89), having reported more than seven sexual partners in a lifetime (vs. < 3 partners; OR 5 2.00; 95%CI: 1.49-2.68), and having reported more than 5 orgasms a month prior to PC diagnosis (vs. 3 orgasms; OR 5 1.59; 95%CI: 1.18-2.15). PC risk was lower for men whose timing of puberty was later than their peers (vs. same as peers; OR 5 0.75; 95%CI: 0.59-0.97), and a smaller risk reduction of was observed in men whose timing of puberty was earlier than their peers (vs. same as peers; OR 5 0.85; 95%CI: 0.61-1.17). No associations were found between PC risk and vertex balding, erectile function, acne, circumcision, vasectomy, asthma or diabetes. These results support a role for adult body size, sexual activity, and adolescent sexual development in PC development.
Introduction
Prostate cancer (PC) is the most common non-cutaneous cancer in men worldwide, with incidence having dramatically risen in developed countries since the introduction of prostate specific antigen (PSA) testing. 1 Internationally, age standardised PC incidence rates are highest in Australia and New Zealand (111.6 new cases per 100,000). 2 Although the aetiology of PC is unclear, there is strong evidence that PC risk increases with advancing age, family history and African ancestry and, possibly, with a history of prostatitis, benign prostatic hyperplasia (BPH) and obesity. [3] [4] [5] [6] [7] Other possible risk factors include the timing of puberty onset, vertex balding pattern and sexual activity [8] [9] [10] [11] [12] [13] [14] Prostate carcinogenesis is associated with altered androgen metabolism, where increased risk is associated with increased production of dihydrotestosterone (DHT), the active metabolite of testosterone. 15 Some of these possible risk factors for PC are also associated with androgen activity, for example, (i) the onset of puberty is associated with elevated androgen levels which have growth promoting effects on the prostate, 16, 17 (ii) balding is associated with elevated levels of androgen receptors and DHT, where inhibition of the latter can stop the progression of balding and even lead to hair regrowth, 18, 19 (iii) obesity is associated with elevated aromatase activity, which converts testosterone to estradiol, thus lowering testosterone levels and consequently DHT production, 15, 20 and (iv) sexual function and desire are associated with high testosterone levels. 21 These associations support an underlying role for androgen regulation in the initiation of PC. 13, 21 The current study examines the associations between PC incidence and a number of potential risk factors for PC, including some androgenic factors such as timing of puberty, balding pattern, body mass index (BMI), and sexual activity, in the New South Wales (NSW) Cancer, Lifestyle and Evaluation of Risk Study (CLEAR).
Methods

Study population
The NSW CLEAR study is an all incident cancer case-control study of NSW residents aged 18 years and over. Approximately 75% of case participants were identified through 'targeted' recruitment sources using medical or health related databases, that provided lists of potential cases who were diagnosed with any cancer type in the preceding 18 months. The remaining case participants were recruited through 'nontargeted' sources including participants who responded to widespread promotion at community events, and face-to-face recruitment at participating oncology clinic rooms. All potential participants were mailed an invitation to participate in the CLEAR study, and were each asked, "What is your cancer type", with prostate cancer listed as an option to choose from. For this analysis we excluded (i) anyone who reported another cancer diagnosis (other than cutaneous keratinocyte cancer) before their diagnosis of prostate cancer or that of their spouse case (for controls), or (ii) was aged younger than 18 years, or (iii) was diagnosed with cancer >18 months ago prior to recruitment. We have referred to all our cases as 'self-reported' prostate cancer cases, as they also represented the 25% of participants who were recruited from sites where databases of histopathologically confirmed cancer were not in use.
CLEAR recruited 10,796 participants (8556 cancer cases and 2240 cancer-free partner controls) between 2006 and 2014. Only men with a self-reported diagnosis of prostate cancer were included as cases in the current analysis. Control participants were cancer-free (except for cutaneous keratinocyte cancers) male partners of women who were cases in the study. Details of the study methods, recruitment strategy and study rationale have been published elsewhere. 
Data collection
All consenting participants were asked to complete a selfadministered paper questionnaire or online questionnaire (available from 2010); 4.6% of participants to whom it was available completed the online questionnaire. Information collected included paternal history of PC, income, region of birth, anthropometric measures, lifestyle, timing of reaching puberty, sexual activity, medical history, and history of PSA testing. The residential Accessibility Remoteness Index of Australia (ARIA plus), which was derived from residential postcode, was used to classify each participants' place of residence. 23 
Data analysis
Participants' demographic characteristics were categorised as follows: Age was derived from age at diagnosis for cases and Pubertal development was based on participants' responses to the questions on timing of commencing shaving and timing of voice break (Later than peers, Same as peers (reference category), Earlier than peers, Non-respondents). Responses to both questions were combined to derive a new variable called "Timing of reaching puberty" which consisted of the following three groups: those who reached at least one of these time points earlier than their peers were grouped as "Earlier than peers", those remaining who reached at least one of these time points later than their peers were grouped as "Later than peers" and those still remaining were grouped as "Same time as peers", and, finally, those who did not give informative responses to both questions were grouped as "Non-respondents".
Body Mass Index (BMI), was calculated as weight (kg)/ [height (m)] 2 using self-reported weight and height before PC diagnosis for cases, or partners' cancer diagnosis for controls, and classified into specified groups established by the World Health Organisation. 24 The number of those in the underweight category (18.5 kg/m 2 ) was small (n 5 8) and therefore was combined with those with a normal BMI. Three categories were formed: Normal/underweight (<25 kg/m . 24 Height and weight, divided into respective quartiles, were also examined for each of their associations with PC risk.
Each participant was asked to self-assess their hair balding pattern before their or their partner's diagnosis, using images from the Hamilton-Norwood scale of male balding patterns showing -Full head of hair (reference category), Frontal balding, Vertex balding and combined Vertex and Frontal balding. . Participants who preferred not to answer any of these questions were grouped as nonrespondents. Participants were also asked if they were diagnosed with other suspected risk factors for prostate cancer such as asthma, diabetes, or had a vasectomy, circumcision or facial acne scarring.
Statistical analysis
We used unconditional logistic regression to estimate odds ratios and 95% confidence intervals (95%CI) for a complete case analysis, where all missing responses for variables in this study, were excluded. Based on relevant published evidence, odds ratios were firstly adjusted for age at diagnosis, place of residence, income, region of birth and paternal history of PC. [11] [12] [13] This level of adjustment is referred to as "Adjusted" 1 in Tables 2 and 3 . Odds ratios were simultaneously adjusted for timing of puberty, BMI, and lifetime number of sexual partners, where appropriate, as each of these factors involve androgen metabolism making them potential confounders of each other's effects; [16] [17] [18] [19] [20] [21] to our knowledge this level of adjustment has not been performed in other studies (each level of adjustment is shown in Table 4 ). The interactions between the main exposures of interest were assessed by including appropriate interaction terms in the regression models.
We carried out the following sensitivity analyses for the association between PC risk and known risk factors for PC (prostatitis, BPH, paternal history of PC): (i) using only NSW Cancer Registry (NSWCR) confirmed PC cases and cancer-free controls, for all those who were recruited until December 2009, as cancer registrations in NSW were only complete until December 2009 at the time of analysis, (ii) cancer-free male controls who were partners of women diagnosed with breast cancer were excluded (to allow for the possibility that women's screening for breast cancer was associated with more PSA testing in their partners), (iii) men classified as "underweight" BMI were excluded to assess whether combining underweight and normal BMI categories affected results, and (iv) men who reported not having any treatment for their cancer were excluded to allow for the possibility that sexual bother after treatment would bias the selfreport of sexual activity. To assess whether our results were affected by the higher proportion of cases being without a partner compared to controls, we conducted a sensitivity analysis restricting the analyses to cases and controls who at the time of completing the questionnaire were married, living with a partner or in a de facto relationship.
All analyses were performed using SAS 9.3 (32) English.
Results
CLEAR recruited 10,796 participants (8556 cancer cases and 2240 cancer-free partner controls) between 2006 and 2014. The average response rate for potential cases across targeted sites was 25.4% while that for controls was 48.6%. 22 There were 1388 eligible PC cases and 1059 cancer-free male controls. Of these, 1181 cases and 875 controls provided sufficient data to be included in the current analysis.
Cases were older than controls, with median ages 65.6 years and 59.0 years respectively. After adjusting for age, cases were more likely to have lived in major cities (OR 5 1.48; 95%CI: 1.19-1.84) or remote areas (OR 5 1.57; 95%CI: 1.15-2.13) than inner regional areas, and also to report routine PSA testing (OR 5 2.85; 95%CI: 2.23-3.64; Table 1 ). There were no significant differences between cases and controls in terms of income or region of birth.
Paternal history of PC, prostatitis and BPH were associated with PC risk (Table 2) . Restricting the analysis to only NSWCR-confirmed PC cases and cancer-free male controls and, separately, to controls for whom the partner's index cancer was not breast cancer, did not appreciably change the strength of these associations (results not shown).
Compared with men who reached the following milestones at the same time as their peers, men who started shaving regularly later than their peers (OR 5 0.72 95%CI: 0.56-0.92) were at lower risk of being diagnosed with PC, and those whose voice broke later than (OR 5 0.73 95%CI: 0.51-1.04) or earlier than (OR 5 0.71 95%CI: 0.48-1.07) their peers, were at lower risk of being diagnosed with PC, although the evidence for this is weak (Table 3) . With respect to "Timing of reaching puberty" which is a combination of both these variables, showed the risk of developing PC was lower for men who reached these milestones later than their peers (vs. same as peers; OR 5 0.75; 95%CI: 0.59-0.97), and a smaller risk reduction was observed for men whose timing of puberty was earlier than their peers (vs. same as peers; OR 5 0.85; 95%CI: 0.61-1.17), although the confidence interval suggests a lower degree of certainty in the latter estimate. The highest risk was for those in the non-respondents category, for all three variables. Men classified as overweight (OR 5 1.24: 95%CI: 0.99-1.55) were at higher risk of PC, while those classified as obese (OR 5 1.44: 95%CI: 1.09-1.89) were at highest risk of PC, compared to normal/underweight men. Excluding those who were underweight from the normal/underweight reference group did not appreciably change the estimated odds ratio. Successive quartiles of height (p trend 50.29; Table 3 ) and weight (p trend 5 0.71; data not shown) were not associated with PC risk.
Having >7 sexual partners in a lifetime was positively associated with PC risk compared to men that have <3 sexual partners in their lifetime (OR 5 2.00; 95%CI: 1.49-2.68). A similar adjusted odds ratio was obtained in a sensitivity analysis excluding men who reported receiving no cancer treatment (OR 5 1.76; 95%CI: 1.30-2.38; data not shown). Men who reported commencing sexual intercourse before 17 years of age were at higher risk of PC (OR5 1.68; 95%CI: 1.18-2.40), than those who were older than 22 years of age.
Risk of PC was also highest for those who reported having >5 orgasms per month in the period just prior to PC diagnosis (OR 5 1.59; 95%CI: 1.18-2.15) than for men who reported 3 or less orgasms. There was no evidence of an association with increasing levels of erectile function and PC risk. Non-respondents to the question on erectile function (OR 5 0.60; 95%CI: 0.42-0.87) and that relating to frequency of orgasms (OR 5 0.70; 95% CI: 0.51-0.95), had lower odds of PC, which may indicate that healthy men may be less inclined to report these indicators of male virility than are men who have been diagnosed with PC. Balding pattern was not associated with PC risk (p 5 0.78).
Additionally adjusting the odds ratios of timing of puberty, BMI, and lifetime number of sexual partners for potential confounding by each of these factors, where appropriate, did not appreciably change the respective odds ratios (Table 4) . There was no substantial evidence for two-way interactions between any pairs of risk factors included in Tables 2 and 3 (P interaction >0.1 in all instances).
Restricting all analyses to only cases (n 5 965) and controls (n 5 860) who are married or who are living with a partner or who are in a de facto relationship, did not appreciably change the point estimates of ORs (Supplementary  Tables S1, S2, S3, S4) .
We found no significant associations between PC risk and having ever smoked (OR5 
Discussion
In addition to a paternal history of PC and histories of prostatitis and BPH, we found the risk of being diagnosed with PC to be positively associated with higher levels of sexual activity and elevated BMI. There was weak evidence that adolescent sexual development may also be a predictor of PC risk, where risk was lower for men who reached puberty later or earlier, than their peers, when compared with men who reached puberty at the same time as their peers. We found no association between PC risk and hair balding pattern. There was no evidence for interactions between the possible risk factors for PC that operate from early in life and the other factors studied, that may affect a man's subsequent risk of prostate cancer, although our study may have been limited by statistical power to detect any such interactions A recent meta-analysis of prospective studies and another by the World Cancer Research Fund (WCRF) have confirmed that BMI is a risk factor for PC. 27, 28 They reported an inverse association between BMI and PC risk among men with low-risk, localised disease, but BMI was positively associated among men with advanced disease. Similar patterns of association by disease aggressiveness were also reported in the 15-year follow-up of The Melbourne Collaborative Cohort Study (MCCS) but not in the Cancer of the Prostate in Sweden study (CPS) participants. 29, 30 Although we found an increased risk of PC among overweight and obese men, this was without regard to the aggressiveness of their cancer as we did not have this information. We found no associations between height or weight, and PC risk in the CLEAR participants. In contrast, the MCCS reported an inverse association between height and PC risk in participants with aggressive disease, and a positive association in participants with non-aggressive disease. 29 WCRF also reported an association between increasing height and greater overall PC risk while the CPS reported that the increase in risk was only for men with low-intermediate risk disease; they found no increasing risk of aggressive or fatal disease. 30 Conversely, a nested case control study in the ProtecT trial reported an association between increasing height and increased risk of advanced PC. 31 There were slight variations in disease classification between these studies; the MCCS and CPS included all men with a Gleason score > 7 as men with aggressive disease, whereas the ProtecT trial also included those with a Gleason score 7 in their advanced disease category.
The role of sexual activity in the aetiology of PC is unlikely to be straight forward due to the multifaceted aspects of sexual activity. We found an association of increasing PC risk for increasing number of sexual partners and decreasing risk for age at first sexual intercourse. A meta-analysis of case control studies, by Dennis et al reported a positive association between increasing number of sexual partners and cancer risk (RR 5 1.2; 95%CI:1.1-1.3), although a recent study by Spence et al showed a reduced risk of PC with more sexual partners (OR 0.78, 95% CI 0.61-1.00). 10, 32 Dennis et al also reported no association with age at first intercourse, but two other case control studies have shown that PC risk was higher for those who commenced sexual activity in their teenage years compared with those who commenced later. 3, 10, 33 Results from the MCCS reported no association between PC risk and frequency of sex but found an inverse association between PC risk and number of ejaculations. We observed no association with erectile function but a positive association between frequency of orgasms and PC risk. Previous evidence to support a role for pubertal development in PC risk is limited and unclear. Although our finding that pubertal growth spurt later than peers was protective against prostate carcinogenesis, is similar to that reported by another Australian-based case control study, we also observed a non-significant risk reduction of similar magnitude for men who experienced early onset of puberty. 11, 12, 14 The lack of statistical significance for the early onset group might be due to the smaller numbers in this group, noting that the proportions in each category for pubertal development in CLEAR (12.1% earlier than peers, 56.6 same as peers, and 23.5% later than peers) are similar to those reported by the Melbourne Collaborative Cohort Study (12.8% earlier than peers, 69.2% same as peers and 18.8% later than peers) and by Giles et al in the Australian Case Control Study (12.6% earlier than peers, 68.6% same as peers and 18.8% later than peers). Regardless the non-significant protective effect for the early onset group in CLEAR is consistent with the results of a USbased case control study which showed no difference in the mean ages for commencing shaving between PC cases and controls, 9 or those from the 19-year follow-up of men from the Kaiser Permanente Medical Care Program which reported no overall association between age at shaving initiation and PC risk. 9 Balding pattern is a potential non-modifiable risk factor for PC, with highest risk reported for men with vertex balding. 8, 11 Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) showed no overall increased PC risk for men with frontal plus moderate vertex balding at age 45 years, but they were at 40% higher risk of developing aggressive disease, compared with men with a full head of hair. 25 The Melbourne Collaborative Cohort Study (MCCS) showed that men with vertex balding at age 40 years had a higher risk of early onset PC, but a lower risk of late onset PC, compared with men without vertex balding at 40 years of age; risk of PC was similar for men with and without vertex balding between ages 60 and 70 years, suggesting that it is important to report age of balding when addressing its effect on PC risk. 26 The lack of such an association in our study, may partly be explained by the absence of information on age of onset for balding which we did not collect. PC development is strongly associated with alterations in androgen metabolism and production of DHT, the active metabolite of testosterone. 20 Each of these factors that we have shown to be associated with PC risk, have the potential to alter androgen metabolism. Levels of androgen receptors and testosterone are elevated during the onset of puberty, 15, 34 which impact the development, maturation, and maintenance of the prostatic gland, consequently affecting both proliferation and differentiation in the luminal epithelium. 15, 34 Balding pattern and PC share common risk factors, such as ageing and genetics, and both factors are hormonallyregulated by DHT. Bald men have higher levels of DHT within the hair follicles and its blockage helps to slow the progression of baldness. 35 Androgen metabolism is altered in obese men due to elevated aromatase activity, which can convert testosterone (T) to estradiol (E), instead of DHT. 34 Aromatase activity is contained within the stroma of the prostate in non-malignant tissue, and is also detected in the epithelium with disease malignancy. 36 These changes to aromatase activity in malignancy can result in overall changes in the T:E ratio to further influence its paracrine activity in cancer development. 36, 37 Sexual function is strongly influenced by circulatory levels of androgens, and its interaction with prostatic glandular cells and their luminal fluid may influence the development of PC. 13 However it is unclear if sexual activity is the cause or consequence of androgen status. 21 A 2-year follow-up of men in the Concord Healthy Aged Men's Project showed that a decline in testosterone, and not DHT or estrogen levels, was strongly associated with a decline in sexual activity and sexual desire, but not erectile function. This may be the basis to explain the fundamental difference between frequency of sexual activity and ejaculation and their effects on PC development. 21 The protective effect of 'late bloomers' on PC risk may be analogous to the effect of age at menarche on breast cancer risk. 38 A shorter duration of exposure to endogenous estrogen, in women who have late menarche, may lower their risk of developing breast cancer. However, these early developmental factors alone cannot solely increase the risk of cancer. The Collaborative Group on Hormonal Factors in Breast Cancer showed that although breast cancer risk increased for each year younger at menarche and for each year older at menopause, these factors were attenuated by adiposity, 38 suggesting that duration of exposure may be significant, but estrogen regulation in this duration is also relevant. We found no evidence for an interaction between PC risk and any of the risk factors that we examined.
A strength of this study is the high concordance between self-report and NSWCR confirmed cases for PC, with a positive predictive value of 99.8%, 22 which justifies the use of self-reported PC cases in our analysis. Sensitivity analyses with only NSWCR confirmed cases and controls (who are confirmed to be cancer-free), and another excluding male controls who were partners of breast cancer cases, did not change the strength of associations of factors of interest and PC risk.
The overall response rate of 25.4% for cases and 48.6% for controls in the CLEAR Study may appear low but it is within the expected range from other studies using a once only postal approach. Nevertheless cases with short survival times (eg men with regional spread or metastatic disease) may be under-represented in our study. Some risk factors examined in the current study have previously been shown to be associated with cases of aggressive disease, and thus an underrepresentation of such cases may have biased results regarding this risk factors towards null. 22, 39 There is potential for bias due to non-differential error from the inaccurate recall of timing of pubertal development. Information on onset of shaving is a surrogate for facial hair growth and depends on the individual's need to want to shave and so does not capture the true commencement of facial hair growth. This variable was correlated with timing of voice break and thus combined to derive a composite variable that represented timing of reaching puberty. Men who could not recall timing of puberty (7.8% controls and 12.3% cases) were grouped separately and showed to have a higher risk of PC, than men who reached these events earlier or at the same as their peers. In addition, based on recent studies that have shown that balding pattern at age 45 is a strong predictor of PC risk, the lack of information on age at balding in the CLEAR study, may have biased our result towards the null. 40 There is potential for differential misclassification bias in the reporting of sexual activity between cases and controls, as a potential disincentive to having active treatment is the high risk of erectile dysfunction. 41 Approximately 85% of the PC cases in CLEAR reported having received active treatment for their cancer, which may influence their response on sexual activity; a sensitivity analysis excluding all men who did not receive any treatment showed no change in the outcome to the questions on sexual activity, suggesting that our questions on sexual history and at various time points may not be subject to this bias.
Despite the possible limitations of this study, our findings are in broad agreement with those from other Australian and international studies. Our results support a role for adult body size, sexual activity and adolescent sexual development in predicting PC risk, suggesting that risk determinants operating early in life may affect men's subsequent PC risk.
